Morges, Switzerland, November 15, 2007 -- Swiss company Leman Cardiovascular (?LCV?) today announced that it has moved to Morges, in the canton of Vaud, as a result of the sale of its facility to Anteis SA, specialised in biopolymers with its 4th generation hyaluronic acids known as Cohesive Polydensified Matrix technology (CPM). Anteis is also from the Lake Geneva region. The sale involves 1,250m2 in Lonay and includes two clean rooms, laboratories, pure water production for solutions, sterilization room and quality assessment and control facilities, all built with latest generation of equipment.
With this sale, Leman Cardiovascular strengthens its financial position to proceed with further development of its product portfolio. The amount of the sale is undisclosed.
Dr Benedict Broennimann, President and CEO of LCV, commented that ?Our move sends a strong message to the market that we are focusing on our core business, the development of innovative products in cardiovascular surgical devices. The headquarters of Leman Cardiovascular in Morges remain the company?s heart of strategic planning and financing. We will continue to manage product development and research from Switzerland, while our Californian subsidiary Hancock Jaffe Laboratories will pursue the operational implementation.?
Leman Cardiovascular, incorporated in Lonay, Switzerland, is a biomedical device company founded in 2004 to develop, manufacture, and market cardiovascular surgical devices. The first product in development is an innovative third generation biological heart valve which the company plans to introduce in 2009. For more information see ww.lemancardiovascular.com.
